Cargando…

Frequency and temporal evolution of COVID-19 vaccination rate among oncological patients undergoing 18F-FDG-PET

PURPOSE: To evaluate the temporal evolution of vaccination against COVID-19 in a Swiss oncological cohort. METHODS: History of complete vaccination (i.e. at least two vaccine doses) against COVID-19 of patients undergoing oncological 18F-FDG PET/CT between February and September 2021 (n = 2613) was...

Descripción completa

Detalles Bibliográficos
Autores principales: Skawran, Stephan, Schiesser, Helen, Maurer, Alexander, Sartoretti, Thomas, Dittli, Manuel, Mader, Cäcilia, Curioni-Fontecedro, Alessandra, Berger, Christoph, Huellner, Martin W., Messerli, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637529/
https://www.ncbi.nlm.nih.gov/pubmed/36372666
http://dx.doi.org/10.1016/j.vaccine.2022.10.089
Descripción
Sumario:PURPOSE: To evaluate the temporal evolution of vaccination against COVID-19 in a Swiss oncological cohort. METHODS: History of complete vaccination (i.e. at least two vaccine doses) against COVID-19 of patients undergoing oncological 18F-FDG PET/CT between February and September 2021 (n = 2613) was taken. Vaccination rate was compared with age-matched national data from the Swiss Federal Office of Public Health. Subgroup differences in temporal evolution of vaccination rate were analyzed by fitting a generalized linear model and determined by significant interaction between, sex, oncological diagnosis, and month of examination. RESULTS: Rate of complete vaccination against COVID-19 steadily increased and reached 81 % in September 2021. The fraction of vaccinated patients in the oncological cohort was higher in the beginning and approached the fraction in the age-matched general Swiss population at the end of the study period. Month of exam (p < 0.001) was the only significant predictor of the vaccination rate. CONCLUSION: Vaccination rate against COVID-19 in a Swiss oncological cohort increased steadily from February to September 2021. Compared to the age-matched general population it was higher in the beginning and similar by the end of the study period. Ethics approval: Trial registration: BASEC 2021-00444, Ethikkommission Zürich (Cantonal Ethics Committee Zurich), Switzerland, registered February 24th 2021.